954 related articles for article (PubMed ID: 8970591)
1. Cutaneous melanomas that defy conventional prognostic indicators.
McCarthy WH; Shaw HM; McCarthy SW; Rivers JK; Thompson JF
Semin Oncol; 1996 Dec; 23(6):709-13. PubMed ID: 8970591
[TBL] [Abstract][Full Text] [Related]
2. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
4. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
5. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system.
Finley JW; Gibbs JF; Rodriguez LM; Letourneau R; Driscoll D; Kraybill W
Am Surg; 2000 Jun; 66(6):527-31; discussion 531-2. PubMed ID: 10888127
[TBL] [Abstract][Full Text] [Related]
6. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
7. The prognostic importance of sentinel lymph node biopsy in thin melanoma.
Ranieri JM; Wagner JD; Wenck S; Johnson CS; Coleman JJ
Ann Surg Oncol; 2006 Jul; 13(7):927-32. PubMed ID: 16788753
[TBL] [Abstract][Full Text] [Related]
8. Enhanced survival in patients with multiple primary melanoma.
Doubrovsky A; Menzies SW
Arch Dermatol; 2003 Aug; 139(8):1013-8. PubMed ID: 12925389
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).
Zettersten E; Sagebiel RW; Miller JR; Tallapureddy S; Leong SP; Kashani-Sabet M
Cancer; 2002 Feb; 94(4):1049-56. PubMed ID: 11920475
[TBL] [Abstract][Full Text] [Related]
10. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
11. Ultra-late recurrence (15 years or longer) of cutaneous melanoma.
Tsao H; Cosimi AB; Sober AJ
Cancer; 1997 Jun; 79(12):2361-70. PubMed ID: 9191524
[TBL] [Abstract][Full Text] [Related]
12. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
13. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy.
Zapas JL; Coley HC; Beam SL; Brown SD; Jablonski KA; Elias EG
J Am Coll Surg; 2003 Sep; 197(3):403-7. PubMed ID: 12946795
[TBL] [Abstract][Full Text] [Related]
14. Depth of invasion and tumor thickness in primary cutaneous malignant melanoma. A study of 2012 cases.
Søndergaard K
Acta Pathol Microbiol Immunol Scand A; 1985 Mar; 93(2):49-55. PubMed ID: 3984735
[TBL] [Abstract][Full Text] [Related]
15. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.
Zogakis TG; Essner R; Wang HJ; Foshag LJ; Morton DL
Ann Surg Oncol; 2007 May; 14(5):1604-11. PubMed ID: 17333418
[TBL] [Abstract][Full Text] [Related]
16. Micrometastasis of a sentinel lymph node in cutaneous melanoma is a significant prognostic factor for disease-free survival, distant-metastasis-free survival, and overall survival.
Moehrle M; Schippert W; Rassner G; Garbe C; Breuninger H
Dermatol Surg; 2004 Oct; 30(10):1319-28. PubMed ID: 15458529
[TBL] [Abstract][Full Text] [Related]
17. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
18. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic study of recurrent Clark level II melanomas.
Glass LF; Guffey JM; Schroer KR; Reintgen D
Semin Surg Oncol; 1993; 9(3):202-7. PubMed ID: 8516604
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy and early-stage melanoma.
Daryanani D; Plukker JT; De Hullu JA; Kuiper H; Nap RE; Hoekstra HJ
Cancer; 2003 May; 97(9):2248-53. PubMed ID: 12712479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]